Get the Stockscreener App
31.37
1.26%
-0.40
Pre-market:
31.33
-0.04
-0.13%
Anaptysbio Inc stock is traded at $31.37, with a volume of 212.12K.
It is down -1.26% in the last 24 hours and up +37.71% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$31.77
Open:
$32.06
24h Volume:
212.12K
Relative Volume:
0.40
Market Cap:
$878.26M
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-5.1595
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
+1.39%
1M Performance:
+37.71%
6M Performance:
+93.17%
1Y Performance:
-1.97%
1-Day Range:
$31.18
$32.38
1-Week Range:
$29.48
$32.53
52-Week Range:
$12.21
$36.54
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
31.37 | 888.70M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
Is AnaptysBio Inc. stock positioned well for digital economyQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
How AnaptysBio Inc. stock reacts to job market dataJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Should you wait for a breakout in AnaptysBio Inc.Gap Up & High Accuracy Investment Entry Signals - newser.com
AnaptysBio Inc. stock prediction for this weekPortfolio Risk Summary & Technical Pattern Alert System - newser.com
How moving averages guide AnaptysBio Inc. tradingGold Moves & Risk Managed Investment Signals - newser.com
Q3 EPS Estimates for AnaptysBio Lifted by Leerink Partnrs - MarketBeat
Can AnaptysBio Inc. (AN6) stock resist broad market declinesWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
Will AnaptysBio Inc. (AN6) stock outperform benchmarks2025 Top Decliners & Free Verified High Yield Trade Plans - newser.com
AnaptysBio splits operations into two companies - MSN
Why AnaptysBio Inc. stock could outperform in 20252025 Institutional Moves & AI Powered Market Trend Analysis - newser.com
AnaptysBio's (ANAB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
HighMark Wealth Management LLC Raises Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for AnaptysBio - MarketBeat
Custom strategy builders for tracking AnaptysBio Inc.Market Sentiment Report & Growth Focused Stock Reports - newser.com
Is AnaptysBio Inc. reversing from oversold territoryWeekly Trade Review & Daily Chart Pattern Signals - newser.com
Applying sector rotation models to AnaptysBio Inc.2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Chart overlay techniques for tracking AnaptysBio Inc.July 2025 Short Interest & Safe Capital Growth Stock Tips - newser.com
Is AnaptysBio Inc. (AN6) stock good for long term investingEarnings Miss & Breakout Confirmation Alerts - newser.com
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.9%Time to Sell? - MarketBeat
HC Wainwright Analysts Cut Earnings Estimates for AnaptysBio - MarketBeat
Biggest stock movers today: UUUU, FLY, and more - MSN
AnaptysBio (NASDAQ:ANAB) Trading 8.9% Higher After Analyst Upgrade - Defense World
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
AnaptysBio (NASDAQ:ANAB) Shares Up 8.9% on Analyst Upgrade - MarketBeat
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $59.00 at HC Wainwright - Defense World
AnaptysBio (NASDAQ:ANAB) Shares Gap Up on Analyst Upgrade - Defense World
A house dividing: Anaptysbio wants separate pipeline, royalty firms - BioWorld MedTech
AnaptysBio Announces Business Separation Plans - The Globe and Mail
AnaptysBio Stock Rise: Analyzing Latest Developments - timothysykes.com
AnaptysBio Split Will Establish Separate Royalty And Biopharma Firms - insights.citeline.com
Biggest stock movers Tuesday: WOLF, UUUU, FLY, and more - MSN
AnaptysBio climbs after Leernik raises PT on investor-friendly spinoff plans - TradingView
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level - Stocktwits
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating - 富途牛牛
AnaptysBio rises on plans to split company - The Pharma Letter
AnaptysBio stock price target raised to $37 from $32 at Leerink Partners - Investing.com Canada
AnaptysBio's Split Announcement Seems 'Awkward' Amid Clinical Activities, Truist Securities Says - MarketScreener
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade - MarketBeat
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
Wedbush Reiterates Outperform Rating on AnaptysBio (ANAB) with $45 Target | ANAB Stock News - GuruFocus
A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $57 to $59 - 富途牛牛
ANAB: HC Wainwright & Co. Raises Price Target to $59, Maintains Buy Rating | ANAB Stock News - GuruFocus
Wedbush Reiterates "Outperform" Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
AnaptysBio stock price target raised to $59 from $38 at H.C. Wainwright - Investing.com Canada
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
29.00 |
8,240 |
238,960 |
9,088 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):